Paediatric Agranulocytosis Associated with Metamizole Treatment.

Omer Kilic Merve İşeri Nepesov Hasan Bora Ulukapı Zeynep Canan Ozdemir Ozcan Bor Ener Çağrı Dinleyici

Published in: Paediatric drugs (2020)

The development of agranulocytosis after the use of metamizole causes long-term hospitalisation and may require the use of medications in treatment management. Considering the availability of alternative options to treat fever and pain, and given the side-effect profile of metamizole, it should not be the preferred, first-line antipyretic treatment in children.

Keyphrases

emergency department
young adults
chronic pain
combination therapy
spinal cord